Login Register Cart 0
Generic placeholder image

Current Nanomedicine

Editor-in-Chief

ISSN (Print): 2468-1873
ISSN (Online): 2468-1881

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Nanostructured Lipid Carriers: A Novel Platform in the Formulation of Targeted Drug Delivery Systems

Author(s): Naga Sri Devi Putchakayala, Keerthana Morusu*, Sireesha Ramisetty and Nagaraju Ravoru*

Volume 15, Issue 1, 2025

Published on: 22 February, 2024

Page: [26 - 49] Pages: 24

DOI: 10.2174/0124681873283751240206071835

Price: $65

Open Access Journals Promotions 2
Abstract

Background: Lipid-based formulations, such as Nanostructured lipid carriers (NLCs), have been thoroughly studied as drug delivery platforms. NLCs are binary systems composed of both solid and liquid lipids that aim to produce a lipidic core that is less ordered. Components of NLCs particularly influence the physicochemical characteristics and efficacy of the final product.

Morphology : They contain a solid matrix at room temperature and are thought to be superior to many other conventional lipids-based nanocarriers, such as solid lipid nanoparticles (SLNs), nanoemulsions, and liposomes because of their improved stability, drug loading capacity, good biocompatibility, enhanced permeability, bioavailability, extended half-life, fewer side effects, tissue- specific delivery and wide range of potential applications.

Significance : NLCs have multiple applications in the manufacturing of pharmaceuticals and cosmetics due to their ease of preparation, the feasibility of scale-up, non-toxic, improved targeting efficiency and potential for site-specific delivery via various routes of administration.

Scope of Review: This review enlightens about the most recent developments of NLCs as a drug delivery system, types of NLCs, current techniques to prepare NLCs, and characterization techniques that are essential for the development of safe, effective and stable formulation. It also encompasses the potential of using NLCs for various administration routes and recent developments in pharmaceutical applications with successful outcomes.

Conclusion: This review certainly provide great insight into formulation considerations using design experts and modification strategies for improved targeting. On the whole, NLCs are broadly explored and preferred lipid nanocarrier systems with several advantages.

Keywords: Nanostructured lipid carriers (NLCs), design of experiments (DOE), box behnken design (BBD), plackett burman design, central composite design (CCD), response surface methodology (RSM).

« Previous Next »
Graphical Abstract

[1]
Alexis F, Rhee JW, Richie JP, Radovic-Moreno AF, Langer R, Farrokhzad OC. New frontiers in nanotechnology for cancer treatment. Urologic Oncology: Seminars and Original Investigations . 2008; 26: pp. (1)74-85.
[http://dx.doi.org/10.1016/j.urolonc.2007.03.017]
[2]
Jaiswal P, Gidwani B, Vyas A. Nanostructured lipid carriers and their current application in targeted drug delivery. Artif Cells Nanomed Biotechnol 2016; 44(1): 27-40.
[http://dx.doi.org/10.3109/21691401.2014.909822] [PMID: 24813223]
[3]
Tapeinos C, Battaglini M, Ciofani G. Advances in the design of solid lipid nanoparticles and nanostructured lipid carriers for targeting brain diseases. J Control Release 2017; 264: 306-32.
[http://dx.doi.org/10.1016/j.jconrel.2017.08.033] [PMID: 28844756]
[4]
Akbarzadeh A, Rezaei-Sadabady R, Davaran S, et al. Liposome: Classification, preparation, and applications. Nanoscale Res Lett 2013; 8(1): 102.
[http://dx.doi.org/10.1186/1556-276X-8-102] [PMID: 23432972]
[5]
Puri A, Loomis K, Smith B, et al. Lipid-based nanoparticles as pharmaceutical drug carriers: From concepts to clinic. Critical Reviews™ in Therapeutic Drug Carrier Systems 2009; 26(3): 523-80.
[http://dx.doi.org/10.1615/CritRevTherDrugCarrierSyst.v26.i6.10]
[6]
Sato Y, Nakamura T, Yamada Y, Harashima H. The nanomedicine rush: New strategies for unmet medical needs based on innovative nano DDS. J Control Release 2021; 330: 305-16.
[http://dx.doi.org/10.1016/j.jconrel.2020.12.032] [PMID: 33358975]
[7]
Eissa NG, Elsabahy M, Allam A. Engineering of smart nanoconstructs for delivery of glucagon-like peptide-1 analogs. Int J Pharm 2021; 597: 120317.
[http://dx.doi.org/10.1016/j.ijpharm.2021.120317] [PMID: 33540005]
[8]
Pardeike J, Hommoss A, Müller RH. Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. Int J Pharm 2009; 366(1-2): 170-84.
[http://dx.doi.org/10.1016/j.ijpharm.2008.10.003] [PMID: 18992314]
[9]
Subramaniam B, Siddik ZH, Nagoor NH. Optimization of nanostructured lipid carriers: Understanding the types, designs, and parameters in the process of formulations. J Nanopart Res 2020; 22(6): 141.
[http://dx.doi.org/10.1007/s11051-020-04848-0]
[10]
Gordillo-Galeano A, Mora-Huertas CE. Solid lipid nanoparticles and nanostructured lipid carriers: A review emphasizing on particle structure and drug release. Eur J Pharm Biopharm 2018; 133: 285-308.
[http://dx.doi.org/10.1016/j.ejpb.2018.10.017] [PMID: 30463794]
[11]
Garcês A, Amaral MH, Sousa Lobo JM, Silva AC. Formulations based on solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) for cutaneous use: A review. Eur J Pharm Sci 2018; 112: 159-67.
[http://dx.doi.org/10.1016/j.ejps.2017.11.023] [PMID: 29183800]
[12]
Mehnert W, Mäder K. Solid lipid nanoparticles. Adv Drug Deliv Rev 2012; 64: 83-101.
[http://dx.doi.org/10.1016/j.addr.2012.09.021] [PMID: 11311991]
[13]
Muller RH, Radtke M, Wissing SA. Solid lipid nanoparticles and nanostructured lipid carriers Encyclopaedia of nanoscience and nanotechnology . American Scientific Publishers 2004; 9: pp. (56)43-56.
[14]
Hajare AA, Mali SS, Ahir AA, et al. Lipid nanoparticles: A modern formulation approach in topical drug delivery systems. J Adv Drug Deliv 2014; 1(1): 30-7.
[15]
Elzeny H, Zhang F, Ali E, et al. Polyphosphoester nanoparticles as biodegradable platform for delivery of multiple drugs and siRNA. Drug Des Devel Ther 2017; 11: 483-96.
[http://dx.doi.org/10.2147/DDDT.S128503] [PMID: 28260861]
[16]
Zhang F, Khan S, Li R, et al. Design and development of multifunctional polyphosphoester-based nanoparticles for ultrahigh paclitaxel dual loading. Nanoscale 2017; 9(41): 15773-7.
[http://dx.doi.org/10.1039/C7NR05935C] [PMID: 29034932]
[17]
Doktorovova S, Souto EB, Silva AM. Nanotoxicology applied to solid lipid nanoparticles and nanostructured lipid carriers – A systematic review of in vitro data. Eur J Pharm Biopharm 2014; 87(1): 1-18.
[http://dx.doi.org/10.1016/j.ejpb.2014.02.005] [PMID: 24530885]
[18]
Zsikó S, Cutcher K, Kovács A, et al. Nanostructured lipid carrier gel for the dermal application of lidocaine: Comparison of skin penetration testing methods. Pharmaceutics 2019; 11(7): 310.
[http://dx.doi.org/10.3390/pharmaceutics11070310] [PMID: 31269690]
[19]
Naseri N, Valizadeh H, Zakeri-Milani P. Solid lipid nanoparticles and nanostructured lipid carriers: Structure, preparation and application. Adv Pharm Bull 2015; 5(3): 305-13.
[http://dx.doi.org/10.15171/apb.2015.043] [PMID: 26504751]
[20]
Li F, Wang Y, Liu Z, Lin X, He H, Tang X. Formulation and characterization of bufadienolides-loaded nanostructured lipid carriers. Drug Dev Ind Pharm 2010; 36(5): 508-17.
[http://dx.doi.org/10.3109/03639040903264397] [PMID: 19821716]
[21]
Pardeike J, Weber S, Haber T, et al. Development of an Itraconazole-loaded nanostructured lipid carrier (NLC) formulation for pulmonary application. Int J Pharm 2011; 419(1-2): 329-38.
[http://dx.doi.org/10.1016/j.ijpharm.2011.07.040] [PMID: 21839157]
[22]
Sharma A, Baldi A. Nanostructured lipid carriers: A review. J Dev Drugs 2018; 7(2): 1-5.
[23]
Haider M, Abdin SM, Kamal L, Orive G. Nanostructured lipid carriers for delivery of chemotherapeutics: A review. Pharmaceutics 2020; 12(3): 288.
[http://dx.doi.org/10.3390/pharmaceutics12030288] [PMID: 32210127]
[24]
Czajkowska-Kośnik A, Szekalska M, Winnicka K. Nanostructured lipid carriers: A potential use for skin drug delivery systems. Pharmacol Rep 2019; 71(1): 156-66.
[http://dx.doi.org/10.1016/j.pharep.2018.10.008] [PMID: 30550996]
[25]
Purohit DK. Nano-lipid carriers for topical application: Current scenario. Asian J Pharm 2016; 10(1)
[26]
Patnaik S, Purohit D, Biswasroy P, Diab WM, Dubey A. Recent advances for commedonal acne treatment by employing lipid nanocarriers topically. Int J Health Sci 2022; 6: 180-205.
[27]
Vijayan V, Aafreen S, Sakthivel S, Reddy KR. Formulation and characterization of solid lipid nanoparticles loaded Neem oil for topical treatment of acne. J Acute Dis 2013; 2(4): 282-6.
[http://dx.doi.org/10.1016/S2221-6189(13)60144-4]
[28]
Salvankar SS, Aghav AA, Mahale DS, Kshirsagar SS, Ratnaparkhi MP. Nanostructured lipid carriers: The advanced lipid carriers and their applications. Int J Pharm Sci Res 2023; 14(2): 547-61.
[http://dx.doi.org/10.13040/IJPSR.0975-8232.14(2).547-61]
[29]
Shidhaye S, Vaidya R, Sutar S, Patwardhan A, Kadam V. Solid lipid nanoparticles and nanostructured lipid carriers--innovative generations of solid lipid carriers. Curr Drug Deliv 2008; 5(4): 324-31.
[http://dx.doi.org/10.2174/156720108785915087] [PMID: 18855604]
[30]
Patel DK, Tripathy S, Nair SK, Kesharwani R. Nanostructured lipid carrier (NLC) a modern approach for topical delivery: A review. World J Pharm Pharm Sci 2013; 2(3): 921-38.
[31]
Salvi VR, Pawar P. Nanostructured lipid carriers (NLC) system: A novel drug targeting carrier. J Drug Deliv Sci Technol 2019; 51: 255-67.
[http://dx.doi.org/10.1016/j.jddst.2019.02.017]
[32]
Mahant S, Rao R, Nanda S. Nanostructured lipid carriers: Revolutionizing skin care and topical therapeutics. Design of nanostructures for versatile therapeutic applications. William Andrew Publishing 2018; pp. 97-136.
[http://dx.doi.org/10.1016/B978-0-12-813667-6.00003-6]
[33]
Das S, Chaudhury A. Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery. AAPS PharmSciTech 2011; 12(1): 62-76.
[http://dx.doi.org/10.1208/s12249-010-9563-0] [PMID: 21174180]
[34]
Betts JN, Johnson MG, Rygiewicz PT, King GA, Andersen CP. Potential for metal contamination by direct sonication of nanoparticle suspensions. Environ Toxicol Chem 2013; 32(4): 889-93.
[http://dx.doi.org/10.1002/etc.2123] [PMID: 23322586]
[35]
Gomaa E, Fathi HA, Eissa NG, Elsabahy M. Methods for preparation of nanostructured lipid carriers. Methods 2022; 199: 3-8.
[http://dx.doi.org/10.1016/j.ymeth.2021.05.003] [PMID: 33992771]
[36]
Shahgaldian P, Da Silva E, Coleman AW, Rather B, Zaworotko MJ. Para-acyl-calix-arene based solid lipid nanoparticles (SLNs): A detailed study of preparation and stability parameters. Int J Pharm 2003; 253(1-2): 23-38.
[http://dx.doi.org/10.1016/S0378-5173(02)00639-7] [PMID: 12593934]
[37]
Kaur S, Nautyal U, Singh R, Singh S, Devi A. Nanostructure lipid carrier (NLC): The new generation of lipid nanoparticles. Asian Pac J Health Sci 2005; 2(2): 76-93.
[38]
Date A, Joshi M, Patravale V. Parasitic diseases: Liposomes and polymeric nanoparticles versus lipid nanoparticles. Adv Drug Deliv Rev 2007; 59(6): 505-21.
[http://dx.doi.org/10.1016/j.addr.2007.04.009] [PMID: 17574295]
[39]
Battaglia L, Gallarate M, Panciani PP, Ugazio E, Sapino S, Peira E, et al. Techniques for the preparation of solid lipid nano and microparticles. Application of Nanotechnology in Drug Delivery. 2014.
[http://dx.doi.org/10.5772/58405]
[40]
Rathod VR, Shah DA, Dave RH. Systematic implementation of quality-by-design (QbD) to develop NSAID-loaded nanostructured lipid carriers for ocular application: preformulation screening studies and statistical hybrid-design for optimization of variables. Drug Dev Ind Pharm 2020; 46(3): 443-55.
[http://dx.doi.org/10.1080/03639045.2020.1724135] [PMID: 32037896]
[41]
Gadag S, Narayan R, Nayak AS, et al. Development and preclinical evaluation of microneedle-assisted resveratrol loaded nanostructured lipid carriers for localized delivery to breast cancer therapy. Int J Pharm 2021; 606: 120877.
[http://dx.doi.org/10.1016/j.ijpharm.2021.120877] [PMID: 34252522]
[42]
Alam T, Khan S, Gaba B, Haider MF, Baboota S, Ali J. Adaptation of quality by design-based development of isradipine nanostructured–lipid carrier and its evaluation for in vitro gut permeation and in vivo solubilization fate. J Pharm Sci 2018; 107(11): 2914-26.
[http://dx.doi.org/10.1016/j.xphs.2018.07.021] [PMID: 30076853]
[43]
Rangaraj N, Pailla SR, Shah S, Prajapati S, Sampathi S. QbD aided development of ibrutinib-loaded nanostructured lipid carriers aimed for lymphatic targeting: Evaluation using chylomicron flow blocking approach. Drug Deliv Transl Res 2020; 10(5): 1476-94.
[http://dx.doi.org/10.1007/s13346-020-00803-7] [PMID: 32519202]
[44]
Tavakoli N, Taymouri S, Saeidi A, Akbari V. Thermosensitive hydrogel containing sertaconazole loaded nanostructured lipid carriers for potential treatment of fungal keratitis. Pharm Dev Technol 2019; 24(7): 891-901.
[http://dx.doi.org/10.1080/10837450.2019.1616755] [PMID: 31062987]
[45]
Czajkowska-Kośnik A, Szymańska E, Czarnomysy R, et al. Nanostructured lipid carriers engineered as topical delivery of etodolac: Optimization and cytotoxicity studies. Materials 2021; 14(3): 596.
[http://dx.doi.org/10.3390/ma14030596] [PMID: 33514018]
[46]
Pokharkar V, Patil-Gadhe A, Palla P. Efavirenz loaded nanostructured lipid carrier engineered for brain targeting through intranasal route: in-vivo pharmacokinetic and toxicity study. Biomed Pharmacother 2017; 94: 150-64.
[http://dx.doi.org/10.1016/j.biopha.2017.07.067] [PMID: 28759752]
[47]
Agrawal Y, Petkar KC, Sawant KK. Development, evaluation and clinical studies of Acitretin loaded nanostructured lipid carriers for topical treatment of psoriasis. Int J Pharm 2010; 401(1-2): 93-102.
[http://dx.doi.org/10.1016/j.ijpharm.2010.09.007] [PMID: 20858539]
[48]
Hassan DH, Shohdy JN, El-Setouhy DA, El-Nabarawi M, Naguib MJ. Compritol-based nanostructured lipid carriers (NLCs) for augmentation of zolmitriptan bioavailability via the transdermal route: in vitro optimization, ex-vivo permeation, in vivo pharmacokinetic study. Pharmaceutics 2022; 14(7): 1484.
[http://dx.doi.org/10.3390/pharmaceutics14071484] [PMID: 35890379]
[49]
Patel HP, Gandhi PA, Chaudhari PS, et al. Clozapine loaded nanostructured lipid carriers engineered for brain targeting via nose-to-brain delivery: Optimization and in vivo pharmacokinetic studies. J Drug Deliv Sci Technol 2021; 64: 102533.
[http://dx.doi.org/10.1016/j.jddst.2021.102533]
[50]
Swidan SA, Mansour ZN, Mourad ZA, et al. DOE, formulation, and optimization of Repaglinide nanostructured lipid carriers. J Appl Pharm Sci 2018; 8(10): 8-16.
[51]
Zhang X, Liu J, Qiao H, et al. Formulation optimization of dihydroartemisinin nanostructured lipid carrier using response surface methodology. Powder Technol 2010; 197(1-2): 120-8.
[http://dx.doi.org/10.1016/j.powtec.2009.09.004]
[52]
Luo Q, Yang J, Xu H, et al. Sorafenib-loaded nanostructured lipid carriers for topical ocular therapy of corneal neovascularization: Development, in-vitro and in vivo study. Drug Deliv 2022; 29(1): 837-55.
[http://dx.doi.org/10.1080/10717544.2022.2048134] [PMID: 35277107]
[53]
Hejri A, Khosravi A, Gharanjig K, Hejazi M. Optimisation of the formulation of β-carotene loaded nanostructured lipid carriers prepared by solvent diffusion method. Food Chem 2013; 141(1): 117-23.
[http://dx.doi.org/10.1016/j.foodchem.2013.02.080] [PMID: 23768336]
[54]
Tamjidi F, Shahedi M, Varshosaz J, Nasirpour A. Design and characterization of astaxanthin-loaded nanostructured lipid carriers. Innov Food Sci Emerg Technol 2014; 26: 366-74.
[http://dx.doi.org/10.1016/j.ifset.2014.06.012]
[55]
Agrawal M, Saraf S, Pradhan M, et al. Design and optimization of curcumin loaded nano lipid carrier system using Box-Behnken design. Biomed Pharmacother 2021; 141: 111919.
[http://dx.doi.org/10.1016/j.biopha.2021.111919] [PMID: 34328108]
[56]
Pradhan M, Singh D, Singh MR. Fabrication, optimization and characterization of Triamcinolone acetonide loaded nanostructured lipid carriers for topical treatment of psoriasis: Application of Box Behnken design, in vitro and ex-vivo studies. J Drug Deliv Sci Technol 2017; 41: 325-33.
[http://dx.doi.org/10.1016/j.jddst.2017.07.024]
[57]
Ma Y, Liu J, Cui X, et al. Hyaluronic acid modified nanostructured lipid carrier for targeting delivery of kaempferol to NSCLC: Preparation, optimization, characterization, and performance evaluation in vitro. Molecules 2022; 27(14): 4553.
[http://dx.doi.org/10.3390/molecules27144553] [PMID: 35889427]
[58]
Ameeduzzafar QM, Qumber M, Alruwaili NK, et al. BBD-based development of itraconazole loaded nanostructured lipid carrier for topical delivery: in vitro evaluation and antimicrobial assessment. J Pharm Innov 2021; 16(1): 85-98.
[http://dx.doi.org/10.1007/s12247-019-09420-5]
[59]
Mahmood A, Rapalli VK, Gorantla S, Waghule T, Singhvi G. Dermatokinetic assessment of luliconazole-loaded nanostructured lipid carriers (NLCs) for topical delivery: QbD-driven design, optimization, and in vitro and ex-vivo evaluations. Drug Deliv Transl Res 2022; 12(5): 1118-35.
[http://dx.doi.org/10.1007/s13346-021-00986-7] [PMID: 33895936]
[60]
Gaba B, Fazil M, Khan S, Ali A, Baboota S, Ali J. Nanostructured lipid carrier system for topical delivery of terbinafine hydrochloride. Bull Fac Pharm Cairo Univ 2015; 53(2): 147-59.
[http://dx.doi.org/10.1016/j.bfopcu.2015.10.001]
[61]
Pereira RR, Testi M, Rossi F, et al. Ucuùba (Virola surinamensis) fat-based nanostructured lipid carriers for nail drug delivery of ketoconazole: Development and optimization using box-Behnken design. Pharmaceutics 2019; 11(6): 284.
[http://dx.doi.org/10.3390/pharmaceutics11060284] [PMID: 31212993]
[62]
Kraisit P, Sarisuta N. Development of triamcinolone acetonide-loaded nanostructured lipid carriers (NLCs) for buccal drug delivery using the Box-Behnken design. Molecules 2018; 23(4): 982.
[http://dx.doi.org/10.3390/molecules23040982] [PMID: 29690622]
[63]
Kang Q, Liu J, Liu XY, et al. Application of quality by design approach to formulate and optimize tripterine loaded in nanostructured lipid carriers for transdermal delivery. J Drug Deliv Sci Technol 2019; 52: 1032-41.
[http://dx.doi.org/10.1016/j.jddst.2019.06.006]
[64]
Jazuli I, Annu , Nabi B, et al. Optimization of nanostructured lipid carriers of lurasidone hydrochloride using Box-Behnken design for brain targeting: in vitro and in vivo studies. J Pharm Sci 2019; 108(9): 3082-90.
[http://dx.doi.org/10.1016/j.xphs.2019.05.001] [PMID: 31077685]
[65]
Emami J, Rezazadeh M, Sadeghi H, Khadivar K. Development and optimization of transferrin-conjugated nanostructured lipid carriers for brain delivery of paclitaxel using Box–Behnken design. Pharm Dev Technol 2017; 22(3): 370-82.
[http://dx.doi.org/10.1080/10837450.2016.1189933] [PMID: 27689412]
[66]
Mathur P, Sharma S, Rawal S, Patel B, Patel MM. Fabrication, optimization, and in vitro evaluation of docetaxel-loaded nanostructured lipid carriers for improved anticancer activity. J Liposome Res 2020; 30(2): 182-96.
[http://dx.doi.org/10.1080/08982104.2019.1614055] [PMID: 31060404]
[67]
Chaudhary S, Garg T, Murthy RSR, Rath G, Goyal AK. Development, optimization and evaluation of long chain nanolipid carrier for hepatic delivery of silymarin through lymphatic transport pathway. Int J Pharm 2015; 485(1-2): 108-21.
[http://dx.doi.org/10.1016/j.ijpharm.2015.02.070] [PMID: 25735668]
[68]
Gilani SJ, Bin-Jumah M, Rizwanullah M, et al. Chitosan coated luteolin nanostructured lipid carriers: Optimization, in vitro-ex-vivo assessments and cytotoxicity study in breast cancer cells. Coatings 2021; 11(2): 158.
[http://dx.doi.org/10.3390/coatings11020158]
[69]
Pyo YC, Tran P, Kim DH, Park JS. Chitosan-coated nanostructured lipid carriers of fenofibrate with enhanced oral bioavailability and efficacy. Colloids Surf B Biointerfaces 2020; 196: 111331.
[http://dx.doi.org/10.1016/j.colsurfb.2020.111331] [PMID: 32906001]
[70]
Chen Y, Feng X, Zhao Y, Zhao X, Zhang X. Mussel-inspired polydopamine coating enhances the intracutaneous drug delivery from nanostructured lipid carriers dependently on a follicular pathway. Mol Pharm 2020; 17(4): 1215-25.
[http://dx.doi.org/10.1021/acs.molpharmaceut.9b01240] [PMID: 32167771]
[71]
Pai RV, Vavia PR. Chitosan oligosaccharide enhances binding of nanostructured lipid carriers to ocular mucins: Effect on ocular disposition. Int J Pharm 2020; 577: 119095.
[http://dx.doi.org/10.1016/j.ijpharm.2020.119095] [PMID: 32004680]
[72]
Eid RK, Ashour DS, Essa EA, El Maghraby GM, Arafa MF. Chitosan coated nanostructured lipid carriers for enhanced in vivo efficacy of albendazole against Trichinella spiralis. Carbohydr Polym 2020; 232: 115826.
[http://dx.doi.org/10.1016/j.carbpol.2019.115826] [PMID: 31952620]
[73]
Zewail M, Nafee N, Helmy MW, Boraie N. Coated nanostructured lipid carriers targeting the joints – An effective and safe approach for the oral management of rheumatoid arthritis. Int J Pharm 2019; 567: 118447.
[http://dx.doi.org/10.1016/j.ijpharm.2019.118447] [PMID: 31226475]
[74]
Bashiri S, Ghanbarzadeh B, Ayaseh A, Dehghannya J, Ehsani A. Preparation and characterization of chitosan-coated nanostructured lipid carriers (CH-NLC) containing cinnamon essential oil for enriching milk and anti-oxidant activity. Lebensm Wiss Technol 2020; 119: 108836.
[http://dx.doi.org/10.1016/j.lwt.2019.108836]
[75]
Bang KH, Na YG, Huh HW, et al. The delivery strategy of paclitaxel nanostructured lipid carrier coated with platelet membrane. Cancers 2019; 11(6): 807.
[http://dx.doi.org/10.3390/cancers11060807] [PMID: 31212681]
[76]
Malgarim Cordenonsi L, Faccendini A, Catanzaro M, et al. The role of chitosan as coating material for nanostructured lipid carriers for skin delivery of fucoxanthin. Int J Pharm 2019; 567: 118487.
[http://dx.doi.org/10.1016/j.ijpharm.2019.118487] [PMID: 31271813]
[77]
Ling Tan JS, Roberts CJ, Billa N. Mucoadhesive chitosan-coated nanostructured lipid carriers for oral delivery of amphotericin B. Pharm Dev Technol 2019; 24(4): 504-12.
[http://dx.doi.org/10.1080/10837450.2018.1515225] [PMID: 30132723]
[78]
Rabelo RS, Oliveira IF, da Silva VM, Prata AS, Hubinger MD. Chitosan coated nanostructured lipid carriers (NLCs) for loading Vitamin D: A physical stability study. Int J Biol Macromol 2018; 119: 902-12.
[http://dx.doi.org/10.1016/j.ijbiomac.2018.07.174] [PMID: 30063935]
[79]
Noor NM, Sheikh K, Somavarapu S, Taylor KMG. Preparation and characterization of dutasteride-loaded nanostructured lipid carriers coated with stearic acid-chitosan oligomer for topical delivery. Eur J Pharm Biopharm 2017; 117: 372-84.
[http://dx.doi.org/10.1016/j.ejpb.2017.04.012] [PMID: 28412472]
[80]
Gao X, Zhang J, Xu Q, Huang Z, Wang Y, Shen Q. Hyaluronic acid-coated cationic nanostructured lipid carriers for oral vincristine sulfate delivery. Drug Dev Ind Pharm 2017; 43(4): 661-7.
[http://dx.doi.org/10.1080/03639045.2016.1275671] [PMID: 28043185]
[81]
Yin J, Hou Y, Yin Y, Song X. Selenium-coated nanostructured lipid carriers used for oral delivery of berberine to accomplish a synergic hypoglycemic effect. Int J Nanomedicine 2017; 12: 8671-80.
[http://dx.doi.org/10.2147/IJN.S144615] [PMID: 29263662]
[82]
Gartziandia O, Herran E, Pedraz JL, Carro E, Igartua M, Hernandez RM. Chitosan coated nanostructured lipid carriers for brain delivery of proteins by intranasal administration. Colloids Surf B Biointerfaces 2015; 134: 304-13.
[http://dx.doi.org/10.1016/j.colsurfb.2015.06.054] [PMID: 26209963]
[83]
Zhang W, Li X, Ye T, et al. Nanostructured lipid carrier surface modified with Eudragit RS 100 and its potential ophthalmic functions. Int J Nanomedicine 2014; 9: 4305-15.
[PMID: 25246787]
[84]
Beloqui A, Solinís MÁ, Rieux A, Préat V, Rodríguez-Gascón A. Dextran–protamine coated nanostructured lipid carriers as mucus-penetrating nanoparticles for lipophilic drugs. Int J Pharm 2014; 468(1-2): 105-11.
[http://dx.doi.org/10.1016/j.ijpharm.2014.04.027] [PMID: 24746410]
[85]
Yang X, Li Y, Li M, Zhang L, Feng L, Zhang N. Hyaluronic acid-coated nanostructured lipid carriers for targeting paclitaxel to cancer. Cancer Lett 2013; 334(2): 338-45.
[http://dx.doi.org/10.1016/j.canlet.2012.07.002] [PMID: 22776563]
[86]
Chen Y, Yuan L, Zhou L, Zhang ZH, Cao W, Wu Q. Effect of cell-penetrating peptide-coated nanostructured lipid carriers on the oral absorption of tripterine. Int J Nanomedicine 2012; 7: 4581-91.
[PMID: 22942642]
[87]
Khajavinia A, Varshosaz J, Dehkordi AJ. Targeting etoposide to acute myelogenous leukaemia cells using nanostructured lipid carriers coated with transferrin. Nanotechnology 2012; 23(40): 405101.
[http://dx.doi.org/10.1088/0957-4484/23/40/405101] [PMID: 22983592]
[88]
Luo Q, Zhao J, Zhang X, Pan W. Nanostructured lipid carrier (NLC) coated with Chitosan Oligosaccharides and its potential use in ocular drug delivery system. Int J Pharm 2011; 403(1-2): 185-91.
[http://dx.doi.org/10.1016/j.ijpharm.2010.10.013] [PMID: 20951778]
[89]
Fang CL, Al-Suwayeh SA, Fang JY. Nanostructured lipid carriers (NLCs) for drug delivery and targeting. Recent Pat Nanotechnol 2013; 7(1): 41-55.
[http://dx.doi.org/10.2174/187221013804484827] [PMID: 22946628]
[90]
Mukherjee S, Ray S, Thakur RS. Solid lipid nanoparticles: A modern formulation approach in drug delivery system. Indian J Pharm Sci 2009; 71(4): 349-58.
[http://dx.doi.org/10.4103/0250-474X.57282] [PMID: 20502539]
[91]
Jores K, Mehnert W, Drechsler M, Bunjes H, Johann C, Mäder K. Investigations on the structure of solid lipid nanoparticles (SLN) and oil-loaded solid lipid nanoparticles by photon correlation spectroscopy, field-flow fractionation and transmission electron microscopy. J Control Release 2004; 95(2): 217-27.
[http://dx.doi.org/10.1016/j.jconrel.2003.11.012] [PMID: 14980770]
[92]
Iqbal MA, Md S, Sahni JK, Baboota S, Dang S, Ali J. Nanostructured lipid carriers system: Recent advances in drug delivery. J Drug Target 2012; 20(10): 813-30.
[http://dx.doi.org/10.3109/1061186X.2012.716845] [PMID: 22931500]
[93]
Svilenov H, Tzachev C. Solid lipid nanoparticles–apromising drug delivery system. Nanomedicine 2014; 8: 188-237.
[94]
Wu M, Fan Y, Lv S, Xiao B, Ye M, Zhu X. Vincristine and temozolomide combined chemotherapy for the treatment of glioma: A comparison of solid lipid nanoparticles and nanostructured lipid carriers for dual drugs delivery. Drug Deliv 2016; 23(8): 2720-5.
[http://dx.doi.org/10.3109/10717544.2015.1058434] [PMID: 26203691]
[95]
Tamjidi F, Shahedi M, Varshosaz J, Nasirpour A. Nanostructured lipid carriers (NLC): A potential delivery system for bioactive food molecules. Innov Food Sci Emerg Technol 2013; 19: 29-43.
[http://dx.doi.org/10.1016/j.ifset.2013.03.002]
[96]
Mahant S, Rao R, Souto EB, Nanda S. Analytical tools and evaluation strategies for nanostructured lipid carrier-based topical delivery systems. Expert Opin Drug Deliv 2020; 17(7): 963-92.
[http://dx.doi.org/10.1080/17425247.2020.1772750] [PMID: 32441158]
[97]
Tichota DM, Silva AC, Sousa Lobo JM, Amaral MH. Design, characterization, and clinical evaluation of argan oil nanostructured lipid carriers to improve skin hydration. Int J Nanomedicine 2014; 9: 3855-64.
[PMID: 25143733]
[98]
Uprit S, Kumar Sahu R, Roy A, Pare A. Preparation and characterization of minoxidil loaded nanostructured lipid carrier gel for effective treatment of alopecia. Saudi Pharm J 2013; 21(4): 379-85.
[http://dx.doi.org/10.1016/j.jsps.2012.11.005] [PMID: 24227958]
[99]
Souto EB, Müller RH. Challenging cosmetics: Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) Science and Applications of Skin Delivery Systems.

[100]
Üner M. Characterization and imaging of solid lipid nanoparticles and nanostructured lipid carriers. Handbook of nanoparticles. Cham: Springer 2016; pp. 117-41.
[http://dx.doi.org/10.1007/978-3-319-15338-4_3]
[101]
Rahman H, Rasedee A, How CW, et al. Zerumbone-loaded nanostructured lipid carriers: Preparation, characterization, and antileukemic effect. Int J Nanomedicine 2013; 8: 2769-81.
[http://dx.doi.org/10.2147/IJN.S45313] [PMID: 23946649]
[102]
Yoon G, Park JW, Yoon IS. Solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs): Recent advances in drug delivery. J Pharm Investig 2013; 43(5): 353-62.
[http://dx.doi.org/10.1007/s40005-013-0087-y]
[103]
Khosa A, Reddi S, Saha RN. Nanostructured lipid carriers for site-specific drug delivery. Biomed Pharmacother 2018; 103: 598-613.
[http://dx.doi.org/10.1016/j.biopha.2018.04.055] [PMID: 29677547]
[104]
Bunjes H, Unruh T. Characterization of lipid nanoparticles by differential scanning calorimetry, X-ray and neutron scattering. Adv Drug Deliv Rev 2007; 59(6): 379-402.
[http://dx.doi.org/10.1016/j.addr.2007.04.013] [PMID: 17658653]
[105]
Moghimi SM, Hunter AC, Andresen TL. Factors controlling nanoparticle pharmacokinetics: An integrated analysis and perspective. Annu Rev Pharmacol Toxicol 2012; 52(1): 481-503.
[http://dx.doi.org/10.1146/annurev-pharmtox-010611-134623] [PMID: 22035254]
[106]
Sahana B, Santra K, Basu S, Mukherjee B. Development of biodegradable polymer based tamoxifen citrate loaded nanoparticles and effect of some manufacturing process parameters on them: A physicochemical and in-vitro evaluation. Int J Nanomedicine 2010; 5: 621-30.
[PMID: 20856837]
[107]
Das S, Ng WK, Tan RBH. Are nanostructured lipid carriers (NLCs) better than solid lipid nanoparticles (SLNs): Development, characterizations and comparative evaluations of clotrimazole-loaded SLNs and NLCs? Eur J Pharm Sci 2012; 47(1): 139-51.
[http://dx.doi.org/10.1016/j.ejps.2012.05.010] [PMID: 22664358]
[108]
Santos S, Neves AR, Silva A, Barbosa M, Reis S, Barbosa J. Nanostructured lipid carriers loaded with resveratrol modulate human dendritic cells. Int J Nanomedicine 2016; 11: 3501-16.
[http://dx.doi.org/10.2147/IJN.S108694] [PMID: 27555771]
[109]
Beloqui A, Solinís MÁ, Rodríguez-Gascón A, Almeida AJ, Préat V. Nanostructured lipid carriers: Promising drug delivery systems for future clinics. Nanomedicine 2016; 12(1): 143-61.
[http://dx.doi.org/10.1016/j.nano.2015.09.004] [PMID: 26410277]
[110]
Soni NK, Sonali LJ, Singh A, Mangla B, Neupane YR, Kohli K. Nanostructured lipid carrier potentiated oral delivery of raloxifene for breast cancer treatment. Nanotechnology 2020; 31(47): 475101.
[http://dx.doi.org/10.1088/1361-6528/abaf81] [PMID: 32886644]
[111]
Liu D, Liu F, Liu Z, Wang L, Zhang N. Tumor specific delivery and therapy by double-targeted nanostructured lipid carriers with anti-VEGFR-2 antibody. Mol Pharm 2011; 8(6): 2291-301.
[http://dx.doi.org/10.1021/mp200402e] [PMID: 21923159]
[112]
Khurana S, Utreja P, Tiwary AK, Jain NK, Jain S. Nanostructured lipid carriers and their application in drug delivery. Int J Biomed Eng Technol 2009; 2(2): 152-71.
[http://dx.doi.org/10.1504/IJBET.2009.022913]
[113]
Jain S, Jain P, Umamaheshwari RB, Jain NK. Transfersomes--a novel vesicular carrier for enhanced transdermal delivery: Development, characterization, and performance evaluation. Drug Dev Ind Pharm 2003; 29(9): 1013-26.
[http://dx.doi.org/10.1081/DDC-120025458] [PMID: 14606665]
[114]
Shailendra S Salvankar, Akshada A Aghav, Devang S Mahale, Shital S Kshirsagar , Mukesh P Ratnaparkhi. Ratnaparkhi nanostructured lipid carriers: the advanced lipid carriers and their application. Int J Pharm Sci Res 2023; 14(2): 547-61.
[115]
Müller RH, Shegokar R, Keck CM. 20 years of lipid nanoparticles (SLN and NLC): Present state of development and industrial applications. Curr Drug Discov Technol 2011; 8(3): 207-27.
[http://dx.doi.org/10.2174/157016311796799062] [PMID: 21291409]
[116]
Pradhan M, Singh D, Murthy SN, Singh MR. Design, characterization and skin permeating potential of Fluocinolone acetonide loaded nanostructured lipid carriers for topical treatment of psoriasis. Steroids 2015; 101: 56-63.
[http://dx.doi.org/10.1016/j.steroids.2015.05.012] [PMID: 26049018]
[117]
Waghule T, Rapalli VK, Singhvi G, et al. Voriconazole loaded nanostructured lipid carriers based topical delivery system: QbD based designing, characterization, in-vitro and ex-vivo evaluation. J Drug Deliv Sci Technol 2019; 52: 303-15.
[http://dx.doi.org/10.1016/j.jddst.2019.04.026]
[118]
Sanad RA, AbdelMalak NS, elBayoomy TS, Badawi AA. Formulation of a novel oxybenzone-loaded nanostructured lipid carriers (NLCs). AAPS PharmSciTech 2010; 11(4): 1684-94.
[http://dx.doi.org/10.1208/s12249-010-9553-2] [PMID: 21107771]
[119]
Zhuang CY, Li N, Wang M, et al. Preparation and characterization of vinpocetine loaded nanostructured lipid carriers (NLC) for improved oral bioavailability. Int J Pharm 2010; 394(1-2): 179-85.
[http://dx.doi.org/10.1016/j.ijpharm.2010.05.005] [PMID: 20471464]
[120]
Elmowafy M, Al-Sanea MM. Nanostructured lipid carriers (NLCs) as drug delivery platform: Advances in formulation and delivery strategies. Saudi Pharm J 2021; 29(9): 999-1012.
[http://dx.doi.org/10.1016/j.jsps.2021.07.015] [PMID: 34588846]
[121]
Radtke M, Souto EB, Müller RH. Nanostructured lipid carriers: A novel generation of solid lipid drug carriers. Pharma Technology Europe 2005; 7(4): 45-50.
[122]
Fathi HA, Allam A, Elsabahy M, Fetih G, El-Badry M. Nanostructured lipid carriers for improved oral delivery and prolonged antihyperlipidemic effect of simvastatin. Colloids Surf B Biointerfaces 2018; 162(162): 236-45.
[http://dx.doi.org/10.1016/j.colsurfb.2017.11.064] [PMID: 29197789]
[123]
Velmurugan R, Selvamuthukumar S. Development and optimization of ifosfamide nanostructured lipid carriers for oral delivery using response surface methodology. Appl Nanosci 2016; 6(2): 159-73.
[http://dx.doi.org/10.1007/s13204-015-0434-6]
[124]
Elmowafy M, Ibrahim HM, Ahmed MA, Shalaby K, Salama A, Hefesha H. Atorvastatin-loaded nanostructured lipid carriers (NLCs): Strategy to overcome oral delivery drawbacks. Drug Deliv 2017; 24(1): 932-41.
[http://dx.doi.org/10.1080/10717544.2017.1337823] [PMID: 28617150]
[125]
Tyagi P, Subramony JA. Nanotherapeutics in oral and parenteral drug delivery: Key learnings and future outlooks as we think small. J Control Release 2018; 272: 159-68.
[http://dx.doi.org/10.1016/j.jconrel.2018.01.009] [PMID: 29355619]
[126]
Jia L, Zhang D, Li Z, et al. Nanostructured lipid carriers for parenteral delivery of silybin: Biodistribution and pharmacokinetic studies. Colloids Surf B Biointerfaces 2010; 80(2): 213-8.
[http://dx.doi.org/10.1016/j.colsurfb.2010.06.008] [PMID: 20621458]
[127]
Sánchez-López E, Espina M, Doktorovova S, Souto EB, García ML. Lipid nanoparticles (SLN, NLC): Overcoming the anatomical and physiological barriers of the eye – Part I – Barriers and determining factors in ocular delivery. Eur J Pharm Biopharm 2017; 110: 70-5.
[http://dx.doi.org/10.1016/j.ejpb.2016.10.009] [PMID: 27789358]
[128]
Diebold Y, Calonge M. Applications of nanoparticles in ophthalmology. Prog Retin Eye Res 2010; 29(6): 596-609.
[http://dx.doi.org/10.1016/j.preteyeres.2010.08.002] [PMID: 20826225]
[129]
Gan L, Wang J, Jiang M, et al. Recent advances in topical ophthalmic drug delivery with lipid-based nanocarriers. Drug Discov Today 2013; 18(5-6): 290-7.
[http://dx.doi.org/10.1016/j.drudis.2012.10.005] [PMID: 23092895]
[130]
Souto EB, Doktorovova S, Gonzalez-Mira E, Egea MA, Garcia ML. Feasibility of lipid nanoparticles for ocular delivery of anti-inflammatory drugs. Curr Eye Res 2010; 35(7): 537-52.
[http://dx.doi.org/10.3109/02713681003760168] [PMID: 20597640]
[131]
Baig MS, Owida H, Njoroge W, Siddiqui A-R, Yang Y. Development and evaluation of cationic nanostructured lipid carriers for ophthalmic drug delivery of besifloxacin. J Drug Deliv Sci Technol 2020; 55: 101496.
[http://dx.doi.org/10.1016/j.jddst.2019.101496]
[132]
Youssef A, Dudhipala N, Majumdar S. Ciprofloxacin loaded nanostructured lipid carriers incorporated into in-situ gels to improve management of bacterial endophthalmitis. Pharmaceutics 2020; 12(6): 572.
[http://dx.doi.org/10.3390/pharmaceutics12060572] [PMID: 32575524]
[133]
Gastaldi L, Battaglia L, Peira E, et al. Solid lipid nanoparticles as vehicles of drugs to the brain: Current state of the art. Eur J Pharm Biopharm 2014; 87(3): 433-44.
[http://dx.doi.org/10.1016/j.ejpb.2014.05.004] [PMID: 24833004]
[134]
Kreuter J. Drug delivery to the central nervous system by polymeric nanoparticles: What do we know? Adv Drug Deliv Rev 2014; 71: 2-14.
[http://dx.doi.org/10.1016/j.addr.2013.08.008] [PMID: 23981489]
[135]
Qi S, Marchaud D, Craig DQM. An investigation into the mechanism of dissolution rate enhancement of poorly water-soluble drugs from spray chilled gelucire 50/13 microspheres. J Pharm Sci 2010; 99(1): 262-74.
[http://dx.doi.org/10.1002/jps.21832] [PMID: 19653284]
[136]
E Eleraky N, M Omar M, A Mahmoud H, A Abou-Taleb H. Nanostructured lipid carriers to mediate brain delivery of Temazepam: design and in vivo study. Pharmaceutics 2020; 12(5): 451.
[http://dx.doi.org/10.3390/pharmaceutics12050451] [PMID: 32422903]
[137]
Patlolla RR, Chougule M, Patel AR, Jackson T, Tata PNV, Singh M. Formulation, characterization and pulmonary deposition of nebulized celecoxib encapsulated nanostructured lipid carriers. J Control Release 2010; 144(2): 233-41.
[http://dx.doi.org/10.1016/j.jconrel.2010.02.006] [PMID: 20153385]
[138]
Sung JC, Pulliam BL, Edwards DA. Nanoparticles for drug delivery to the lungs. Trends Biotechnol 2007; 25(12): 563-70.
[http://dx.doi.org/10.1016/j.tibtech.2007.09.005] [PMID: 17997181]
[139]
Jaques PA, Kim CS. Measurement of total lung deposition of inhaled ultrafine particles in healthy men and women. Inhal Toxicol 2000; 12(8): 715-31.
[http://dx.doi.org/10.1080/08958370050085156] [PMID: 10880153]
[140]
Patil-Gadhe A, Kyadarkunte A, Patole M, Pokharkar V. Montelukast-loaded nanostructured lipid carriers: Part II Pulmonary drug delivery and in vitro–in vivo aerosol performance. Eur J Pharm Biopharm 2014; 88(1): 169-77.
[http://dx.doi.org/10.1016/j.ejpb.2014.07.007] [PMID: 25078860]
[141]
Garbuzenko OB, Kbah N, Kuzmov A, Pogrebnyak N, Pozharov V, Minko T. Inhalation treatment of cystic fibrosis with lumacaftor and ivacaftor co-delivered by nanostructured lipid carriers. J Control Release 2019; 296: 225-31.
[http://dx.doi.org/10.1016/j.jconrel.2019.01.025] [PMID: 30677435]
[142]
Abdelkawi A, Slim A, Zinoune Z, Pathak Y. Surface modification of metallic nanoparticles for targeting drugs. Coatings 2023; 13(9): 1660.
[http://dx.doi.org/10.3390/coatings13091660]
[143]
Choi M, Choi WK, Jung CH, Kim SB. The surface modification and characterization of SiO2 nanoparticles for higher foam stability. Sci Rep 2020; 10(1): 19399.
[http://dx.doi.org/10.1038/s41598-020-76464-w] [PMID: 33173140]
[144]
Ammar HO, Ghorab MM, Mostafa DM, Ibrahim ES. Folic acid loaded lipid nanocarriers with promoted skin antiaging and antioxidant efficacy. J Drug Deliv Sci Technol 2016; 31: 72-82.
[http://dx.doi.org/10.1016/j.jddst.2015.11.007]
[145]
Reineccius GA. Liposomes for controlled-release in the food-industry. Encapsulation and Controlled Release of Food Ingredients. 590: 113-31.
[146]
Acosta E. Bioavailability of nanoparticles in nutrient and nutraceutical delivery. Curr Opin Colloid Interface Sci 2009; 14(1): 3-15.
[http://dx.doi.org/10.1016/j.cocis.2008.01.002]
[147]
Espín JC, García-Conesa MT, Tomás-Barberán FA. Nutraceuticals: Facts and fiction. Phytochemistry 2007; 68(22-24): 2986-3008.
[http://dx.doi.org/10.1016/j.phytochem.2007.09.014] [PMID: 17976666]
[148]
Huang Q, Yu H, Ru Q. Bioavailability and delivery of nutraceuticals using nanotechnology. J Food Sci 2010; 75(1): R50-7.
[http://dx.doi.org/10.1111/j.1750-3841.2009.01457.x] [PMID: 20492195]
[149]
Katouzian I, Faridi Esfanjani A, Jafari SM, Akhavan S. Formulation and application of a new generation of lipid nano-carriers for the food bioactive ingredients. Trends Food Sci Technol 2017; 68: 14-25.
[http://dx.doi.org/10.1016/j.tifs.2017.07.017]
[150]
Koynova R, Wang L, MacDonald RC. An intracellular lamellar–nonlamellar phase transition rationalizes the superior performance of some cationic lipid transfection agents. Proc Natl Acad Sci USA 2006; 103(39): 14373-8.
[http://dx.doi.org/10.1073/pnas.0603085103] [PMID: 16983097]
[151]
Gibbs BF, Kermasha S, Alli I, Mulligan CN. Encapsulation in the food industry: A review. Int J Food Sci Nutr 1999; 50(3): 213-24.
[http://dx.doi.org/10.1080/096374899101256] [PMID: 10627837]
[152]
Mohammadi A, Jafari SM, Mahoonak AS, Ghorbani M. Liposomal/nanoliposomal encapsulation of food-relevant enzymes and their application in the food industry. Food Bioprocess Technol 2021; 14(1): 23-38.
[http://dx.doi.org/10.1007/s11947-020-02513-x]
[153]
Liu D, Liu Z, Wang L, Zhang C, Zhang N. Nanostructured lipid carriers as novel carrier for parenteral delivery of docetaxel. Colloids Surf B Biointerfaces 2011; 85(2): 262-9.
[http://dx.doi.org/10.1016/j.colsurfb.2011.02.038] [PMID: 21435845]
[154]
Chauhan I, Yasir M, Verma M, Singh AP. Nanostructured lipid carriers: A groundbreaking approach for transdermal drug delivery. Adv Pharm Bull 2020; 10(2): 150-65.
[http://dx.doi.org/10.34172/apb.2020.021] [PMID: 32373485]
[155]
Silvia DRa. Acetylated cashew gum biopolymer micro and nanoparticles for drug delivery. BR1020180149962A2., 2018.
[156]
Silvia KFF. Water-soluble nanoporous solid foam for controlled drug release in mucous membranes. BR1020170073220A2., 2017.
[157]
Mat Jalaluddin NS, Asem M, Harikrishna JA, Ahmad Fuaad AAH. Recent progress on nanocarriers for topical- mediated rnai strategies for crop protection-a review. Molecules 2023; 28(6): 2700.
[http://dx.doi.org/10.3390/molecules28062700]
[158]
Lal R, Landon PB, Mo A. The regents of the university of california, assignee. Nanostructured carriers for guided and targeted on-demand substance delivery. US 20170119891, 2017.
[159]
Geun KB, Jun PD. Korea food research institute, assignee. nano-structured lipid carrier comprising α-tocopherol and preparing method thereof KR101777616B, 2017.
[160]
Ismail R, Qiuhong L, Linan HL, Hassan HA, Yunmei Z, Basili MH, et al. Malaysian Palm Oil Council, assignee. Preparation of nanostructured lipid carriers (NLC) method and products made. CN102283809B, 2016.
[161]
Lafuente EG, Lucea GG, Rincón SV, Navarro MP, Moreno OI, Hornes GA, et al. Praxis biopharma research institute, assignee. Lipid nanoparticles for wound healing. EP2821077A1, 2015.
[162]
Ujang Z, Ab Rashid AH, Suboh SK, Ahmad Z, Othman MN, Diah MM. A method for producing nanolipid formulation for skin care and/or repair and a nanolipid formulation of the same. WO2015105407A1, 2015.
[163]
Sachdeva MS, Patlolla R. Florida agricultural and mechanical university, assignee. Nanoparticle formulations for skin delivery. US8715736B2, 2014.
[164]
Summer S, Hongxia W. Suzhou nakang biotechnology Co., Ltd., assignee. Coenzyme Q nanostructured lipid carrier and preparation method thereof. CN101658468A, 2013.
[165]
Jianping L, Ji W. China Pharmaceutical University, assignee. Bionic lovastatin nano-structured lipid carrier and preparation method thereof. CN102935077A, 2013.
[166]
Petit JLV, Gonzalez RD, Botello AF. Lipotec SA, assignee. Lipid nanoparticle capsules. 2013/0017239A1, 2013.
[167]
Qiang X, Xueyang D. Southeast University, assignee. Composite anti-screening agent nanostructured lipid carrier and preparation method thereof. CN102688152A, 2012.
[168]
Jian DY, Fuqiang YH, Yuan H. Use of nano structured lipid carrier drug feeding system CN101129335A, 2010.
[169]
Bondi ML, Giammona G, Craparo EF, Drago F. Consiglio Nazionale Delle Richerche., assignee. Nanostructured lipid carriers containing riluzole and pharmaceutical formulations containing said particles EP20070764871, 2009.
[170]
Liu D, Ning R, Song J, Li L, Minghui L, Shubin L, et al. Shenyang wanai pride medical technology Co., Ltd. Assignee. Novel nano-lipid carrier for injection embodying paclitaxel series substances and preparation method thereof. CN101366697A, 2009; 18
[171]
Popowski KD, Moatti A, Scull G, et al. Inhalable dry powder mRNA vaccines based on extracellular vesicles. Matter 2022; 5(9): 2960-74.
[http://dx.doi.org/10.1016/j.matt.2022.06.012]
[172]
Hasham R, Suhaimi SH, Rosli NA, Aziz R, Sarmidi MR. . A nanostructured lipid carrier encapsulates orthosiphon stamineus extract. MYPI 2016300023, 2018.
[173]
Zhidong L, Rui H, Yumei W, et al. A kind of gambogicacid nano structured lipid carrier and preparation method thereof of cyclic peptide modification. CN108853054, 2018.
[174]
Wang B, Wang Q, Bai L. A kind of polymer thermal sensitive liposome loading yeast dextran and carnosic acid. CN108904450, 2018.
[175]
Hong Geun P, Geun P, Ko Sang H, et al. Curcumin nanostructured lipid carrier having improved heat stability and efficient stabilization heat treatment method thereof KR1020190024397, 2019.
[176]
Behl G, Kumari S, O'reilly N, et al. Ocular drug delivery. WO2019123420A1, 2019.
[177]
Xie M, Xu M, Chen X, Zhou M. A kind of nano structured lipid carrier and its preparation method and application of synergistic treatment glioma. CN110013471, 2019.
[178]
Sarmidi MR, Mohamad ST, Hasham R. A nanostructured lipid carrier encapsulates bromelain extract. MYPI 2018300001., 2018.
[179]
Pathania A, Kumar M, Sarup P, Bhatt S, Pandurangan A, Saini V. Novel nanostructured lipid carrierbased ophthalmic controlled release formulation for treatment in fungal keratitis. IN201811021213, 2019.
[180]
Fox CB, Khandhar AP, Van HN, Erasmus JG, Lin SS. Nanostructured lipid carriers and stable emulsions and uses thereof. EP3638207, 2020.
[181]
Thuy VN, Van TV, Dao AH, Lee BJ. Nanostructured lipid carriers and their potential applications for versatile drug delivery via oral administration. OpenNano 2022; 8: 100064.
[182]
Naghipoor J, Rabczuk T. A mechanistic model for drug release from PLGA-based drug eluting stent: A computational study. Comput Biol Med 2017; 90(90): 15-22.
[http://dx.doi.org/10.1016/j.compbiomed.2017.09.001] [PMID: 28917119]
[183]
Versypt AN, Pack DW, Braatz RD. Mathematical modeling of drug delivery from autocatalytically degradable PLGA microspheres—A review. J Control Release 2013; 165(1): 29-37.
[184]
Valizadeh N, Rabczuk T. Isogeometric analysis of hydrodynamics of vesicles using a monolithic phase-field approach. Comput Methods Appl Mech Eng 2022; 388: 114191.
[http://dx.doi.org/10.1016/j.cma.2021.114191]

Rights & Permissions Print Cite
Article Metrics
13
1
Wayfinder Image
Open Access Journals Promotions
© 2024 Bentham Science Publishers | Privacy Policy